↓ Skip to main content

Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia

Overview of attention for article published in Annals of Hematology, April 2018
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (64th percentile)
  • Good Attention Score compared to outputs of the same age and source (74th percentile)

Mentioned by

twitter
7 tweeters

Citations

dimensions_citation
12 Dimensions

Readers on

mendeley
10 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia
Published in
Annals of Hematology, April 2018
DOI 10.1007/s00277-018-3311-z
Pubmed ID
Authors

Jonas Paludo, Jithma P. Abeykoon, Amanda Shreders, Stephen M. Ansell, Shaji Kumar, Sikander Ailawadhi, Rebecca L. King, Amber B. Koehler, Craig B. Reeder, Francis K. Buadi, Angela Dispenzieri, Martha Q. Lacy, David Dingli, Thomas E. Witzig, Ronald S. Go, Wilson I. Gonsalves, Taxiarchis Kourelis, Rahma Warsame, Nelson Leung, Thomas M. Habermann, Suzanne Hayman, Yi Lin, Robert A. Kyle, S. Vincent Rajkumar, Morie A. Gertz, Prashant Kapoor

Abstract

The treatment approaches for Waldenstrom macroglobulinemia (WM) are largely based upon information from single-arm phase II trials, without comparative data. We compared the efficacy of two commonly used regimens in routine practice (bendamustine-rituximab (BR) and dexamethasone, rituximab plus cyclophosphamide (DRC)) and evaluated their activity with respect to the patients' MYD88L265P mutation status. Of 160 consecutive patients, 60 received BR (43 with relapsed/refractory WM) and 100 received DRC (50 had relapsed/refractory WM). In the treatment-naïve setting, overall response rate (ORR) was 93% with BR versus 96% with DRC (p = 0.55). Two-year progression-free survival (PFS) with BR and DRC was 88 and 61%, respectively (p = 0.07). In salvage setting, ORR was 95% with BR versus 87% with DRC, p = 0.45; median PFS with BR was 58 versus 32 months with DRC (2-year PFS was 66 versus 53%; p = 0.08). Median disease-specific survival was not reached with BR versus 166 months with DRC (p = 0.51). The time-to-event endpoints and depth of response were independent of the MYD88 mutation status. Grade ≥ 3 adverse events of both regimens were comparable. A trend for longer PFS was observed with BR although the regimens have comparable toxicities. The activity of BR and DRC appears to be unaffected by patients' MYD88 mutation status.

Twitter Demographics

The data shown below were collected from the profiles of 7 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 10 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 10 100%

Demographic breakdown

Readers by professional status Count As %
Unspecified 3 30%
Student > Master 3 30%
Researcher 1 10%
Librarian 1 10%
Professor > Associate Professor 1 10%
Other 1 10%
Readers by discipline Count As %
Medicine and Dentistry 6 60%
Unspecified 3 30%
Pharmacology, Toxicology and Pharmaceutical Science 1 10%

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 August 2018.
All research outputs
#3,712,053
of 13,350,484 outputs
Outputs from Annals of Hematology
#136
of 1,139 outputs
Outputs of similar age
#96,047
of 270,365 outputs
Outputs of similar age from Annals of Hematology
#7
of 27 outputs
Altmetric has tracked 13,350,484 research outputs across all sources so far. This one has received more attention than most of these and is in the 71st percentile.
So far Altmetric has tracked 1,139 research outputs from this source. They receive a mean Attention Score of 2.4. This one has done well, scoring higher than 87% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 270,365 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 64% of its contemporaries.
We're also able to compare this research output to 27 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.